DARMSTADT, Germany--(BUSINESS WIRE)--Merck, a leading science and technology company, announced the closing of the transaction to acquire HUB Organoids Holding B.V. (HUB) following regulatory ...

Karen Madden, PhD, senior vice president and chief technology officer, MilliporeSigma. The U.S. and Canadian Life sciences business of Merck KGaA, Darmstadt, Germany, has set out to establish a ...

Through its U.S. and Canada life science business MilliporeSigma, Merck KGaA is acquiring Dutch company HUB Organoids. The deal is expected to be finalized by the end of 2024, according to a Dec. 17 ...

Relative to its peer companies, Merck KGaA has a compelling valuation from which to realize its upside potential through its ...

The acquisition of HUB Organoids reflects the strategy of MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany, to enable wider access to HUB’s technology for ...

Discover how patient-derived organoid technology is transforming infectious disease research and drug development. Join us to explore: The science behind HUB Organoid Technology and its creation from ...

Discover how a new procedure reverses the polarity of typical basolateral-out organoids to form versatile apical-out organoids. In this webinar, Lloyd Bod and Nathaniel Robichaud will discuss how ...

Hubrecht Organoid Technology (HUB), and the health insurance companies CZ, Zilveren Kruis, and Menzis announced today that they will start a €3 million validation trial for use of HUB Organoid ...

Reinforces company’s commitment to differentiated solutions that enable faster and more effective drug development HUB’s organoid offering complements company’s cell culture portfolio of media, ...

The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the U.S. and Canada business of Merck KGaA, Darmstadt, Germany in ...